Drugs / Guipi Granules
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06245642 | Mar 2024 → Jan 2025 | myalgic encephalomeyelitis/chronic fatigue syndrome | Heilongjiang Quanle Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Guipi Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06245642 ↗ |
| Route | Oral | “Experimental group: Basic treatment + Compound Ciwujia Granules + Guipi Granules simulator orally for 6 weeks; Positive drug control group: basic treatment + Guipi Granules +...” NCT06245642 ↗ |